PMID- 15043203
OWN - NLM
STAT- MEDLINE
DCOM- 20040428
LR  - 20191108
IS  - 1570-162X (Print)
IS  - 1570-162X (Linking)
VI  - 1
IP  - 2
DP  - 2003 Apr
TI  - Dendritic cells and the promise of therapeutic vaccines for human 
      immunodeficiency virus (HIV)-1.
PG  - 205-16
AB  - Treatment of human immunodeficiency virus (HIV)-1 infection with potent 
      antiretroviral medications has provided considerable clinical benefit. However 
      because of the limitations of current therapy, innovative approaches are needed 
      to better control HIV-1 infection. Several studies have suggested that robust 
      CD4+ T helper and CD8+ T cell responses may contribute to the immunologic control 
      of HIV-1 infection in certain individuals. Most chronically infected patients, 
      however, cannot control the infection and may benefit from stimulation of 
      cellular immunity with immunotherapy. Dendritic cells (DCs) are potent 
      professional antigen-presenting cells (APCs) and have a central role in directing 
      the adaptive immune response to pathogens. The ability of DCs to stimulate naive 
      T cells has long been thought to be crucial in initiating an effective immune 
      response. As DCs are uniquely situated at the interface between the innate and 
      adaptive immune systems, they are currently under intense scrutiny as potential 
      adjuvants for vaccines in many clinical settings. Studies in healthy volunteers 
      and patients with cancer have shown that antigen-pulsed DCs can boost both CD8+ 
      and CD4+ T cell responses in vivo. Based on these promising findings, ex vivo 
      antigen-pulsed DCs are being actively investigated in studies aimed at developing 
      a therapeutic vaccine for individuals with HIV-1 infection.
FAU - Walsh, Stephen R
AU  - Walsh SR
AD  - Division of Infectious Diseases, Department of Medicine, Massachusetts General 
      Hospital, Boston, MA 02114, USA. swalsh@partners.org
FAU - Bhardwaj, Nina
AU  - Bhardwaj N
FAU - Gandhil, Rajesh T
AU  - Gandhil RT
LA  - eng
GR  - AI-007387-12/AI/NIAID NIH HHS/United States
GR  - AI-01443-04/AI/NIAID NIH HHS/United States
GR  - AI-39516/AI/NIAID NIH HHS/United States
GR  - AI-44628/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Netherlands
TA  - Curr HIV Res
JT  - Current HIV research
JID - 101156990
RN  - 0 (AIDS Vaccines)
RN  - 0 (Adjuvants, Immunologic)
SB  - IM
MH  - AIDS Vaccines/immunology/*pharmacology/therapeutic use
MH  - Adjuvants, Immunologic/pharmacology/therapeutic use
MH  - Dendritic Cells/*immunology
MH  - HIV Infections/*immunology
MH  - HIV-1/*immunology
MH  - Humans
MH  - Immunotherapy/methods
MH  - Virus Replication/immunology
RF  - 159
EDAT- 2004/03/27 05:00
MHDA- 2004/04/29 05:00
CRDT- 2004/03/27 05:00
PHST- 2004/03/27 05:00 [pubmed]
PHST- 2004/04/29 05:00 [medline]
PHST- 2004/03/27 05:00 [entrez]
AID - 10.2174/1570162033485285 [doi]
PST - ppublish
SO  - Curr HIV Res. 2003 Apr;1(2):205-16. doi: 10.2174/1570162033485285.